ISRCTN74277350进行中（未招募）Unknown
Does in-bed Cycling delivered within 48 hours of mechanical ventilation, rEduce the occurrence of Delirium in critically ill patients (FRECycl-D): a mixed-methods feasibility randomised controlled trial
适应症
试验速览
- 阶段
- Unknown
- 状态
- 进行中（未招募）
- 入组人数
- 84
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Adults (aged 18 years and above)
- •2. Unplanned ICU admissions
- •3. MV initiated within =48 hours of ICU admission
- •4. Expected to remain on MV >72 hours
排除标准
- •1. Contra-indications to mobilisation
- •2. Known or suspected cognitive impairment and/or learning difficulties
- •3. Plan is for palliation/withdrawal of treatment
- •4. Immobile prior to ICU admission
- •5. Body weight over the device safety limit (=135 kg)
- •6. BMI <18.5 kg/m2
- •7. Planned ICU admission
- •8. Pregnancy
- •9. Prisoners
研究者
相似试验
招募中
不适用
Comparative study of labor induction with Foley Tube for 24 hours and 48 hours in pregnant women with previous cesarean sectioRBR-4bzxqjjGuilherme Nicolau Camara
进行中（未招募）
不适用
A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy - C2303E1EUCTR2009-013901-33-ATovartis Pharma Services AG112
进行中（未招募）
不适用
A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy - C2303E1Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's diseaseMedDRA version: 12.0Level: LLTClassification code 10036370Term: Posterior uveitisEUCTR2009-013901-33-GRovartis Pharma Services AG102
进行中（未招募）
不适用
A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy (SHIELD Study) - C2303E1, SHIELD StudyAdjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's diseaseMedDRA version: 12.0Level: LLTClassification code 10036370Term: Posterior uveitisEUCTR2009-013901-33-DEovartis Pharma Services AG112
进行中（未招募）
不适用
A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapyAdjunctive therapy to standard-of-care for the treatment of intermediate uveitis, posterior uveitis or panuveitis secondary to Behçet's diseaseMedDRA version: 12.0Level: LLTClassification code 10036370Term: Posterior uveitisMedDRA version: 12.1Level: LLTClassification code 10022557Term: Intermediate uveitisMedDRA version: 12.1Level: LLTClassification code 10033687Term: PanuveitisEUCTR2009-013901-33-FRovartis Pharma Services AG146